 | Today early-stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing companies to access promising new and emerging compounds and technologies. To become a successful player within the life science industry it is crucial to understand the changing dynamics of the industry’s early stage deal-making trends. |
|
 | China has become an attractive destination for R&D as new opportunities have emerged following its WTO (World Trade Organization) accession. Development has accelerated both industrially and scientifically, and today the Chinese pharmaceutical market is worth around $US12 billion. |
|
 | Business Opportunities in China: The impact of the WTOKey points covered in this report:> The development of the Chinese pharmaceutical industry and its current status> Changes in the industry on China's accession to the WTO> The competitiveness of the Chinese pharmaceutical industry in the international market> The R&D and business opportunities for pharmaceutical firms considering alliances in China> Significant points for consideration for companies looking to capture business opportunities in China. |
|
| Paul Ranson's comprehensive report covers the contractual features of the outsourcing process from start to finish. This report includes information on the legal aspects of outsourcing services at all stages of product development, manufacturing and exploitation, including preclinical and clinical research, manufacture, logistics and sales. |
|
.gif) | Pharmalicensing's best selling licensing report has returned, fully revised and updated with new statistics, data and expert advice.Licensing is at it's peak - in-licensed products now generate over 30% of the revenues of the major pharmaceutical companies and some 25% of the ‘blockbusters’ of recent years have a history of cross-company licensing, that's why it's more important than ever to understand and secure the right deal and terms. This report examines the key factors that must be considered when drawing up a suitable contract, and includes highlights and tips for negotiating and understanding complex license agreements. |
|
 | Partneringdesk™ Deals and Alliances therapy reports provide a comprehensive summary of the deals and alliances announced in the therapeutic area in the last five years, in a clear and accessible printable format.Every deal entry includes financial information where disclosed, such as headline values and upfront payments. |
|
| Partneringdesk™ Deals BriefingsDealmaking activity of 50 of the top pharmaceutical companiesPartneringdesk™ Deals Briefings provide a comprehensive summary of the deals and alliances announced by fifty of the top pharmaceutical and biotechnology companies in the last five years, in a clear and accessible printable format. |
|
| Weekly deals, alliance and financing intelligence direct to your desktopPartneringweek™ is an interactive spreadsheet containing the week's deals, alliances and financing announcements from the worldwide biopharma sector. Each issue of Partneringweek includes over 80 deals and alliances announcements, and over 20 financing announcements. |
|
| All the year's deals in one placeWant to know what your competitors are doing? Want to benchmark your deals against others in your therapeutic area or see how the finances of different deal types compare?Partneringreview™ brings all the year’s deals into focus in one place. This latest edition sees innovative additions including a fuller coverage of Japanese deals and alliances, and a brand new financings volume detailing investment information in the form of grants/award, private financings, loans, IPO and public placements from investors. Volume 1 also includes details of mergers and acquisitions. |
|
